Table 2. Clinical outcomes according to presence of scaffold discontinuity assessed by means of optical coherence tomography.

	Discontinuity (n=5)	No discontinuity (n=44)	Difference (95% CI)	p-value
Patient-oriented composite endpoint¶	1 (20.0)	9 (20.5)	–0.5 (–37.5 to 36.6)	1.000
Device-oriented composite endpoint‡	1 (20.0)	5 (11.4)	8.6 (–27.7 to 44.9)	0.495
All-cause death	0 (0.0)	0 (0.0)	–
Myocardial infarction	0 (0.0)	0 (0.0)	–
Definite or probable device thrombosis	0 (0.0)	0 (0.0)	–
Target lesion revascularisation	1 (20.0)	5 (11.4)	8.6 (–27.7 to 44.9)	0.495
Target vessel revascularisation	1 (20.0)	7 (15.9)	4.1 (–32.6 to 40.8)	1.000
Non-target vessel revascularisation	0 (0.0)	3 (6.8)	–6.8 (–14.3 to 0.6)	1.000
Data are presented as n (%). *Device-oriented composite endpoint is defined as the composite of cardiac death, target vessel myocardial infarction, and target lesion revascularisation. ¶Patient-oriented composite endpoint is defined as the composite of all-cause death, any myocardial infarction, and any revascularisation. 95% CI: 95% confidence interval; MgBRS: magnesium-based bioresorbable scaffold; SES: sirolimus-eluting stent